Zacks: Brokerages Anticipate Kindred Biosciences Inc (NASDAQ:KIN) Will Announce Earnings of -$0.35 Per Share

Equities research analysts expect Kindred Biosciences Inc (NASDAQ:KIN) to announce earnings of ($0.35) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Kindred Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.32). Kindred Biosciences posted earnings per share of ($0.39) in the same quarter last year, which suggests a positive year over year growth rate of 10.3%. The company is scheduled to report its next earnings report after the market closes on Tuesday, November 12th.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

According to Zacks, analysts expect that Kindred Biosciences will report full year earnings of ($1.52) per share for the current year, with EPS estimates ranging from ($1.62) to ($1.37). For the next financial year, analysts expect that the company will report earnings of ($1.25) per share, with EPS estimates ranging from ($1.46) to ($0.88). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Kindred Biosciences.

KIN has been the subject of several research reports. B. Riley cut shares of Kindred Biosciences from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $18.00 to $8.50 in a research note on Tuesday, July 16th. Zacks Investment Research upgraded shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Kindred Biosciences in a research note on Wednesday, July 31st. BidaskClub upgraded shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, November 5th. Finally, ValuEngine raised shares of Kindred Biosciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 15th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $14.28.

Several large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC purchased a new stake in Kindred Biosciences in the 3rd quarter worth $46,000. Gabelli Funds LLC increased its holdings in Kindred Biosciences by 23.1% in the 3rd quarter. Gabelli Funds LLC now owns 16,000 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 3,000 shares in the last quarter. Teton Advisors Inc. grew its holdings in shares of Kindred Biosciences by 5.9% during the third quarter. Teton Advisors Inc. now owns 36,000 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 2,000 shares in the last quarter. Dalton Greiner Hartman Maher & Co. purchased a new stake in shares of Kindred Biosciences during the third quarter worth $971,000. Finally, Morgan Stanley grew its holdings in shares of Kindred Biosciences by 67.4% during the second quarter. Morgan Stanley now owns 1,901,961 shares of the biopharmaceutical company’s stock worth $15,843,000 after buying an additional 765,748 shares in the last quarter. 68.18% of the stock is owned by hedge funds and other institutional investors.

NASDAQ KIN traded up $0.05 during trading on Friday, reaching $8.75. 89,700 shares of the company’s stock traded hands, compared to its average volume of 182,740. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.36 and a quick ratio of 10.79. Kindred Biosciences has a 12-month low of $5.96 and a 12-month high of $14.00. The company’s 50 day simple moving average is $7.52 and its two-hundred day simple moving average is $7.81. The firm has a market cap of $345.30 million, a price-to-earnings ratio of -5.47 and a beta of 0.45.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Further Reading: Calculating net profit and net profit margin ratio

Get a free copy of the Zacks research report on Kindred Biosciences (KIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kindred Biosciences (NASDAQ:KIN)

Leave a Reply

Your email address will not be published. Required fields are marked *